SEHK:9995Biotechs
A Look At RemeGen’s Valuation After Its Strong Full Year Profit Turnaround
Why RemeGen’s latest earnings matter for investors
RemeGen (SEHK:9995) has just posted full year 2025 results, moving from a net loss to a net profit, with sales and earnings per share both higher than the previous year.
See our latest analysis for RemeGen.
That earnings turnaround appears to be reflected in the share price, with a 1-day share price return of 10.92% and a year-to-date share price return of 15.82%. The 1-year total shareholder return is also very large and suggests strong...